Soligenix’s CiVax booster vaccine shows efficacy against COVID-19 variants

Soligenix (SNGX) announced a publication describing the preclinical efficacy of CiVax, a thermostabilized subunit vaccine against SARS-CoV-2. Using custom-developed immunoassays, the combination of a primary adenovirus vaccine – COVID-19 Vaccine AstraZeneca – coupled with a CiVax booster was shown to induce broader protection against COVID-19 variants in non-human primates than a 2-shot mRNA series in humans. CiVax is the company’s heat stable subunit vaccine candidate for the prevention of COVID-19, the infection caused by SARS-CoV-2. “Our ThermoVax platform has successfully thermostabilized vaccines for ricin toxin, for filoviruses such as Ebola, Sudan and Marburg, and for COVID, and as such is a well-established thermostabilization strategy that enhances the standard protein subunit vaccination technology. We believe this enhancement makes protein subunit vaccines, the gold standard for safe vaccines, competitive with other vaccine technologies, such as mRNA, which have much more stringent cold-storage requirements,” stated CEO Christopher Schaber. “The ability of CiVax to induce rapid broad immune coverage, including against SARS-CoV-2 variants, even when administered after other primary vaccination series, is another marked advantage…This platform may also aid in the preparation for future pandemics.”